nodes	percent_of_prediction	percent_of_DWPC	metapath
Erythromycin—CYP3A5—Beclomethasone—psoriasis	0.049	0.0632	CbGbCtD
Erythromycin—CYP1A2—Clobetasol propionate—psoriasis	0.0482	0.0621	CbGbCtD
Erythromycin—ABCC1—Cyclosporine—psoriasis	0.0399	0.0514	CbGbCtD
Erythromycin—SLCO1A2—Prednisolone—psoriasis	0.0398	0.0513	CbGbCtD
Erythromycin—SLCO1A2—Hydrocortisone—psoriasis	0.0377	0.0486	CbGbCtD
Erythromycin—SLCO1A2—Prednisone—psoriasis	0.0376	0.0484	CbGbCtD
Erythromycin—SLCO1A2—Cyclosporine—psoriasis	0.0356	0.0459	CbGbCtD
Erythromycin—CYP2B6—Cholecalciferol—psoriasis	0.0286	0.0368	CbGbCtD
Erythromycin—SLC22A7—Methotrexate—psoriasis	0.0269	0.0347	CbGbCtD
Erythromycin—CYP1A2—Methoxsalen—psoriasis	0.0253	0.0326	CbGbCtD
Erythromycin—SLCO1A2—Dexamethasone—psoriasis	0.0235	0.0302	CbGbCtD
Erythromycin—ABCC1—Methotrexate—psoriasis	0.0211	0.0272	CbGbCtD
Erythromycin—CYP3A7—Hydrocortisone—psoriasis	0.0209	0.0269	CbGbCtD
Erythromycin—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0209	0.0269	CbGbCtD
Erythromycin—CYP3A7—Cyclosporine—psoriasis	0.0197	0.0254	CbGbCtD
Erythromycin—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0197	0.0254	CbGbCtD
Erythromycin—CYP3A5—Mycophenolate mofetil—psoriasis	0.0195	0.0252	CbGbCtD
Erythromycin—SLCO1A2—Methotrexate—psoriasis	0.0189	0.0243	CbGbCtD
Erythromycin—CYP3A4—Calcitriol—psoriasis	0.017	0.022	CbGbCtD
Erythromycin—CYP3A5—Hydrocortisone—psoriasis	0.0157	0.0202	CbGbCtD
Erythromycin—CYP3A5—Cyclosporine—psoriasis	0.0148	0.0191	CbGbCtD
Erythromycin—CYP3A4—Methoxsalen—psoriasis	0.0133	0.0171	CbGbCtD
Erythromycin—CYP3A7—Dexamethasone—psoriasis	0.013	0.0167	CbGbCtD
Erythromycin—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.013	0.0167	CbGbCtD
Erythromycin—ABCB1—Mycophenolate mofetil—psoriasis	0.0127	0.0164	CbGbCtD
Erythromycin—CYP2B6—Dexamethasone—psoriasis	0.0124	0.0159	CbGbCtD
Erythromycin—ABCB1—Betamethasone—psoriasis	0.0109	0.014	CbGbCtD
Erythromycin—ABCB1—Prednisolone—psoriasis	0.0108	0.0139	CbGbCtD
Erythromycin—ABCB1—Hydrocortisone—psoriasis	0.0102	0.0131	CbGbCtD
Erythromycin—ABCB1—Prednisone—psoriasis	0.0102	0.0131	CbGbCtD
Erythromycin—CYP3A5—Dexamethasone—psoriasis	0.00974	0.0126	CbGbCtD
Erythromycin—ABCB1—Cyclosporine—psoriasis	0.00963	0.0124	CbGbCtD
Erythromycin—CYP3A4—Cholecalciferol—psoriasis	0.00878	0.0113	CbGbCtD
Erythromycin—CYP3A4—Mycophenolate mofetil—psoriasis	0.00761	0.00981	CbGbCtD
Erythromycin—CYP3A4—Triamcinolone—psoriasis	0.00761	0.00981	CbGbCtD
Erythromycin—CYP3A4—Betamethasone—psoriasis	0.00653	0.00842	CbGbCtD
Erythromycin—CYP3A4—Prednisolone—psoriasis	0.00644	0.0083	CbGbCtD
Erythromycin—ABCB1—Dexamethasone—psoriasis	0.00634	0.00817	CbGbCtD
Erythromycin—CYP3A4—Hydrocortisone—psoriasis	0.00611	0.00787	CbGbCtD
Erythromycin—CYP3A4—Prednisone—psoriasis	0.00609	0.00784	CbGbCtD
Erythromycin—CYP3A4—Cyclosporine—psoriasis	0.00577	0.00743	CbGbCtD
Erythromycin—ABCB1—Methotrexate—psoriasis	0.0051	0.00657	CbGbCtD
Erythromycin—CYP3A4—Dexamethasone—psoriasis	0.0038	0.0049	CbGbCtD
Erythromycin—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00134	0.0619	CbGpPWpGaD
Erythromycin—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00112	0.0519	CbGpPWpGaD
Erythromycin—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.00083	0.0384	CbGpPWpGaD
Erythromycin—MLNR—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000817	0.0378	CbGpPWpGaD
Erythromycin—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000811	0.0375	CbGpPWpGaD
Erythromycin—MLNR—Peptide ligand-binding receptors—CCL20—psoriasis	0.000633	0.0293	CbGpPWpGaD
Erythromycin—MLNR—GPCR ligand binding—HCAR2—psoriasis	0.000622	0.0288	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—IL22—psoriasis	0.000491	0.0227	CbGpPWpGaD
Erythromycin—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000488	0.0226	CbGpPWpGaD
Erythromycin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000466	0.0215	CbGpPWpGaD
Erythromycin—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00046	0.0213	CbGpPWpGaD
Erythromycin—MLNR—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000425	0.0196	CbGpPWpGaD
Erythromycin—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000378	0.0175	CbGpPWpGaD
Erythromycin—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000377	0.0174	CbGpPWpGaD
Erythromycin—MLNR—GPCR downstream signaling—HCAR2—psoriasis	0.000352	0.0163	CbGpPWpGaD
Erythromycin—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000344	0.0159	CbGpPWpGaD
Erythromycin—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00034	0.0157	CbGpPWpGaD
Erythromycin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000337	0.0156	CbGpPWpGaD
Erythromycin—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000332	0.0154	CbGpPWpGaD
Erythromycin—MLNR—GPCR ligand binding—CCL20—psoriasis	0.000323	0.015	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—HCAR2—psoriasis	0.000319	0.0148	CbGpPWpGaD
Erythromycin—Pruritus—Calcitriol—psoriasis	0.000294	0.00145	CcSEcCtD
Erythromycin—Rash—Methoxsalen—psoriasis	0.000293	0.00145	CcSEcCtD
Erythromycin—Urticaria—Acitretin—psoriasis	0.000293	0.00145	CcSEcCtD
Erythromycin—Jaundice—Mycophenolate mofetil—psoriasis	0.000293	0.00145	CcSEcCtD
Erythromycin—Abdominal pain—Acitretin—psoriasis	0.000292	0.00144	CcSEcCtD
Erythromycin—Skin exfoliation—Methotrexate—psoriasis	0.00029	0.00144	CcSEcCtD
Erythromycin—Irritability—Betamethasone—psoriasis	0.00029	0.00143	CcSEcCtD
Erythromycin—Irritability—Dexamethasone—psoriasis	0.00029	0.00143	CcSEcCtD
Erythromycin—Injury—Prednisone—psoriasis	0.000287	0.00142	CcSEcCtD
Erythromycin—Diarrhoea—Calcitriol—psoriasis	0.000284	0.0014	CcSEcCtD
Erythromycin—Pancreatitis—Triamcinolone—psoriasis	0.000283	0.0014	CcSEcCtD
Erythromycin—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000279	0.0129	CbGpPWpGaD
Erythromycin—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000277	0.0128	CbGpPWpGaD
Erythromycin—Nausea—Methoxsalen—psoriasis	0.000276	0.00137	CcSEcCtD
Erythromycin—Hepatitis—Cyclosporine—psoriasis	0.000276	0.00137	CcSEcCtD
Erythromycin—Anorexia—Hydroxyurea—psoriasis	0.000276	0.00137	CcSEcCtD
Erythromycin—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000273	0.0126	CbGpPWpGaD
Erythromycin—Hypersensitivity—Acitretin—psoriasis	0.000272	0.00134	CcSEcCtD
Erythromycin—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000271	0.00134	CcSEcCtD
Erythromycin—Hepatitis—Mycophenolate mofetil—psoriasis	0.00027	0.00133	CcSEcCtD
Erythromycin—Hallucination—Mycophenolate mofetil—psoriasis	0.000268	0.00133	CcSEcCtD
Erythromycin—Vertigo—Mycophenolic acid—psoriasis	0.000267	0.00132	CcSEcCtD
Erythromycin—Vomiting—Calcitriol—psoriasis	0.000264	0.0013	CcSEcCtD
Erythromycin—Palpitations—Mycophenolic acid—psoriasis	0.000263	0.0013	CcSEcCtD
Erythromycin—Rash—Calcitriol—psoriasis	0.000262	0.00129	CcSEcCtD
Erythromycin—Pruritus—Acitretin—psoriasis	0.000261	0.00129	CcSEcCtD
Erythromycin—Pruritus—Fluocinolone Acetonide—psoriasis	0.00026	0.00129	CcSEcCtD
Erythromycin—Tinnitus—Cyclosporine—psoriasis	0.000258	0.00127	CcSEcCtD
Erythromycin—Convulsion—Mycophenolic acid—psoriasis	0.000258	0.00127	CcSEcCtD
Erythromycin—Chest pain—Mycophenolic acid—psoriasis	0.000253	0.00125	CcSEcCtD
Erythromycin—Diarrhoea—Acitretin—psoriasis	0.000253	0.00125	CcSEcCtD
Erythromycin—Irritability—Prednisone—psoriasis	0.000252	0.00125	CcSEcCtD
Erythromycin—Decreased appetite—Hydroxyurea—psoriasis	0.000252	0.00125	CcSEcCtD
Erythromycin—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000252	0.00125	CcSEcCtD
Erythromycin—Tinnitus—Mycophenolate mofetil—psoriasis	0.000251	0.00124	CcSEcCtD
Erythromycin—Discomfort—Mycophenolic acid—psoriasis	0.00025	0.00124	CcSEcCtD
Erythromycin—Pain—Hydroxyurea—psoriasis	0.000248	0.00123	CcSEcCtD
Erythromycin—Arrhythmia—Cyclosporine—psoriasis	0.000247	0.00122	CcSEcCtD
Erythromycin—Nausea—Calcitriol—psoriasis	0.000246	0.00122	CcSEcCtD
Erythromycin—Confusional state—Mycophenolic acid—psoriasis	0.000245	0.00121	CcSEcCtD
Erythromycin—Hallucination—Hydrocortisone—psoriasis	0.000244	0.00121	CcSEcCtD
Erythromycin—Dizziness—Acitretin—psoriasis	0.000244	0.00121	CcSEcCtD
Erythromycin—Dizziness—Fluocinolone Acetonide—psoriasis	0.000243	0.0012	CcSEcCtD
Erythromycin—Arrhythmia—Mycophenolate mofetil—psoriasis	0.000241	0.00119	CcSEcCtD
Erythromycin—Feeling abnormal—Hydroxyurea—psoriasis	0.000239	0.00118	CcSEcCtD
Erythromycin—Dysgeusia—Cyclosporine—psoriasis	0.000236	0.00117	CcSEcCtD
Erythromycin—Vomiting—Acitretin—psoriasis	0.000235	0.00116	CcSEcCtD
Erythromycin—Vomiting—Fluocinolone Acetonide—psoriasis	0.000234	0.00116	CcSEcCtD
Erythromycin—Rash—Acitretin—psoriasis	0.000233	0.00115	CcSEcCtD
Erythromycin—Rash—Fluocinolone Acetonide—psoriasis	0.000232	0.00115	CcSEcCtD
Erythromycin—Anorexia—Mycophenolic acid—psoriasis	0.000231	0.00114	CcSEcCtD
Erythromycin—Dysgeusia—Mycophenolate mofetil—psoriasis	0.00023	0.00114	CcSEcCtD
Erythromycin—Arrhythmia—Prednisolone—psoriasis	0.000225	0.00111	CcSEcCtD
Erythromycin—Pancreatitis—Prednisone—psoriasis	0.000224	0.00111	CcSEcCtD
Erythromycin—Arrhythmia—Hydrocortisone—psoriasis	0.000219	0.00109	CcSEcCtD
Erythromycin—Nausea—Acitretin—psoriasis	0.000219	0.00108	CcSEcCtD
Erythromycin—Erythema—Prednisolone—psoriasis	0.000219	0.00108	CcSEcCtD
Erythromycin—Nausea—Fluocinolone Acetonide—psoriasis	0.000219	0.00108	CcSEcCtD
Erythromycin—Vertigo—Cyclosporine—psoriasis	0.000216	0.00107	CcSEcCtD
Erythromycin—Erythema—Hydrocortisone—psoriasis	0.000214	0.00106	CcSEcCtD
Erythromycin—Hypersensitivity—Hydroxyurea—psoriasis	0.000213	0.00106	CcSEcCtD
Erythromycin—Decreased appetite—Mycophenolic acid—psoriasis	0.000211	0.00104	CcSEcCtD
Erythromycin—Vertigo—Mycophenolate mofetil—psoriasis	0.000211	0.00104	CcSEcCtD
Erythromycin—Irritability—Methotrexate—psoriasis	0.000211	0.00104	CcSEcCtD
Erythromycin—Hallucination—Dexamethasone—psoriasis	0.000209	0.00103	CcSEcCtD
Erythromycin—Hallucination—Betamethasone—psoriasis	0.000209	0.00103	CcSEcCtD
Erythromycin—Convulsion—Cyclosporine—psoriasis	0.000208	0.00103	CcSEcCtD
Erythromycin—Pain—Mycophenolic acid—psoriasis	0.000208	0.00103	CcSEcCtD
Erythromycin—Palpitations—Mycophenolate mofetil—psoriasis	0.000207	0.00103	CcSEcCtD
Erythromycin—Arrhythmia—Triamcinolone—psoriasis	0.000207	0.00102	CcSEcCtD
Erythromycin—Chest pain—Cyclosporine—psoriasis	0.000205	0.00101	CcSEcCtD
Erythromycin—Liver function test abnormal—Methotrexate—psoriasis	0.000204	0.00101	CcSEcCtD
Erythromycin—Convulsion—Mycophenolate mofetil—psoriasis	0.000203	0.00101	CcSEcCtD
Erythromycin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000203	0.0094	CbGpPWpGaD
Erythromycin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000203	0.00938	CbGpPWpGaD
Erythromycin—Discomfort—Cyclosporine—psoriasis	0.000202	0.001	CcSEcCtD
Erythromycin—Erythema—Triamcinolone—psoriasis	0.000201	0.000996	CcSEcCtD
Erythromycin—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000201	0.00928	CbGpPWpGaD
Erythromycin—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.0002	0.00926	CbGpPWpGaD
Erythromycin—Feeling abnormal—Mycophenolic acid—psoriasis	0.0002	0.000989	CcSEcCtD
Erythromycin—Chest pain—Mycophenolate mofetil—psoriasis	0.0002	0.000988	CcSEcCtD
Erythromycin—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000199	0.000983	CcSEcCtD
Erythromycin—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000198	0.000981	CcSEcCtD
Erythromycin—Diarrhoea—Hydroxyurea—psoriasis	0.000198	0.00098	CcSEcCtD
Erythromycin—Confusional state—Cyclosporine—psoriasis	0.000198	0.000979	CcSEcCtD
Erythromycin—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000198	0.00915	CbGpPWpGaD
Erythromycin—Discomfort—Mycophenolate mofetil—psoriasis	0.000197	0.000976	CcSEcCtD
Erythromycin—Dysgeusia—Triamcinolone—psoriasis	0.000197	0.000975	CcSEcCtD
Erythromycin—Vertigo—Prednisolone—psoriasis	0.000197	0.000973	CcSEcCtD
Erythromycin—Anaphylactic shock—Cyclosporine—psoriasis	0.000196	0.000971	CcSEcCtD
Erythromycin—Confusional state—Mycophenolate mofetil—psoriasis	0.000193	0.000955	CcSEcCtD
Erythromycin—Vertigo—Hydrocortisone—psoriasis	0.000192	0.00095	CcSEcCtD
Erythromycin—Abdominal pain—Mycophenolic acid—psoriasis	0.000192	0.000949	CcSEcCtD
Erythromycin—Dizziness—Hydroxyurea—psoriasis	0.000192	0.000948	CcSEcCtD
Erythromycin—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000192	0.000947	CcSEcCtD
Erythromycin—Convulsion—Prednisolone—psoriasis	0.00019	0.000938	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—HCAR2—psoriasis	0.000189	0.00873	CbGpPWpGaD
Erythromycin—Arrhythmia—Dexamethasone—psoriasis	0.000187	0.000927	CcSEcCtD
Erythromycin—Arrhythmia—Betamethasone—psoriasis	0.000187	0.000927	CcSEcCtD
Erythromycin—Anorexia—Cyclosporine—psoriasis	0.000187	0.000926	CcSEcCtD
Erythromycin—Pancreatitis—Methotrexate—psoriasis	0.000187	0.000925	CcSEcCtD
Erythromycin—Convulsion—Hydrocortisone—psoriasis	0.000185	0.000916	CcSEcCtD
Erythromycin—Vomiting—Hydroxyurea—psoriasis	0.000184	0.000911	CcSEcCtD
Erythromycin—Discomfort—Prednisolone—psoriasis	0.000184	0.000911	CcSEcCtD
Erythromycin—Abdominal discomfort—Methotrexate—psoriasis	0.000183	0.000905	CcSEcCtD
Erythromycin—Rash—Hydroxyurea—psoriasis	0.000183	0.000904	CcSEcCtD
Erythromycin—MLNR—GPCR downstream signaling—CCL20—psoriasis	0.000183	0.00845	CbGpPWpGaD
Erythromycin—Erythema—Dexamethasone—psoriasis	0.000183	0.000903	CcSEcCtD
Erythromycin—Erythema—Betamethasone—psoriasis	0.000183	0.000903	CcSEcCtD
Erythromycin—Anorexia—Mycophenolate mofetil—psoriasis	0.000183	0.000903	CcSEcCtD
Erythromycin—Hallucination—Prednisone—psoriasis	0.000182	0.000899	CcSEcCtD
Erythromycin—Vertigo—Triamcinolone—psoriasis	0.000181	0.000894	CcSEcCtD
Erythromycin—Discomfort—Hydrocortisone—psoriasis	0.00018	0.000889	CcSEcCtD
Erythromycin—Anaphylactic shock—Prednisolone—psoriasis	0.000179	0.000884	CcSEcCtD
Erythromycin—MLNR—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000178	0.00822	CbGpPWpGaD
Erythromycin—Anaphylactic shock—Hydrocortisone—psoriasis	0.000174	0.000863	CcSEcCtD
Erythromycin—Convulsion—Triamcinolone—psoriasis	0.000174	0.000863	CcSEcCtD
Erythromycin—Nausea—Hydroxyurea—psoriasis	0.000172	0.000851	CcSEcCtD
Erythromycin—Pruritus—Mycophenolic acid—psoriasis	0.000172	0.000849	CcSEcCtD
Erythromycin—MLNR—Peptide ligand-binding receptors—CXCL8—psoriasis	0.000171	0.00791	CbGpPWpGaD
Erythromycin—Decreased appetite—Cyclosporine—psoriasis	0.000171	0.000844	CcSEcCtD
Erythromycin—Discomfort—Triamcinolone—psoriasis	0.000169	0.000837	CcSEcCtD
Erythromycin—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.000169	0.00781	CbGpPWpGaD
Erythromycin—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000169	0.000834	CcSEcCtD
Erythromycin—Pain—Cyclosporine—psoriasis	0.000168	0.00083	CcSEcCtD
Erythromycin—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000166	0.000823	CcSEcCtD
Erythromycin—Anorexia—Hydrocortisone—psoriasis	0.000166	0.000823	CcSEcCtD
Erythromycin—Diarrhoea—Mycophenolic acid—psoriasis	0.000166	0.000821	CcSEcCtD
Erythromycin—MLNR—Signaling by GPCR—CCL20—psoriasis	0.000166	0.00767	CbGpPWpGaD
Erythromycin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000164	0.00761	CbGpPWpGaD
Erythromycin—Anaphylactic shock—Triamcinolone—psoriasis	0.000164	0.000813	CcSEcCtD
Erythromycin—Vertigo—Betamethasone—psoriasis	0.000164	0.000812	CcSEcCtD
Erythromycin—Vertigo—Dexamethasone—psoriasis	0.000164	0.000812	CcSEcCtD
Erythromycin—Pain—Mycophenolate mofetil—psoriasis	0.000164	0.00081	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—TAGAP—psoriasis	0.000164	0.00757	CbGpPWpGaD
Erythromycin—Arrhythmia—Prednisone—psoriasis	0.000163	0.000807	CcSEcCtD
Erythromycin—Feeling abnormal—Cyclosporine—psoriasis	0.000162	0.0008	CcSEcCtD
Erythromycin—Gastrointestinal pain—Cyclosporine—psoriasis	0.000161	0.000794	CcSEcCtD
Erythromycin—Dizziness—Mycophenolic acid—psoriasis	0.00016	0.000794	CcSEcCtD
Erythromycin—Erythema—Prednisone—psoriasis	0.000159	0.000787	CcSEcCtD
Erythromycin—Convulsion—Betamethasone—psoriasis	0.000158	0.000783	CcSEcCtD
Erythromycin—Convulsion—Dexamethasone—psoriasis	0.000158	0.000783	CcSEcCtD
Erythromycin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000158	0.00732	CbGpPWpGaD
Erythromycin—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000158	0.000781	CcSEcCtD
Erythromycin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000157	0.000775	CcSEcCtD
Erythromycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000157	0.00724	CbGpPWpGaD
Erythromycin—Urticaria—Cyclosporine—psoriasis	0.000156	0.000771	CcSEcCtD
Erythromycin—Abdominal pain—Cyclosporine—psoriasis	0.000155	0.000768	CcSEcCtD
Erythromycin—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000154	0.00715	CbGpPWpGaD
Erythromycin—Vomiting—Mycophenolic acid—psoriasis	0.000154	0.000763	CcSEcCtD
Erythromycin—Discomfort—Betamethasone—psoriasis	0.000154	0.00076	CcSEcCtD
Erythromycin—Discomfort—Dexamethasone—psoriasis	0.000154	0.00076	CcSEcCtD
Erythromycin—Rash—Mycophenolic acid—psoriasis	0.000153	0.000757	CcSEcCtD
Erythromycin—Pain—Prednisolone—psoriasis	0.000153	0.000756	CcSEcCtD
Erythromycin—Hepatitis—Methotrexate—psoriasis	0.000153	0.000755	CcSEcCtD
Erythromycin—Urticaria—Mycophenolate mofetil—psoriasis	0.000152	0.000752	CcSEcCtD
Erythromycin—Decreased appetite—Hydrocortisone—psoriasis	0.000152	0.00075	CcSEcCtD
Erythromycin—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000151	0.000749	CcSEcCtD
Erythromycin—Pain—Hydrocortisone—psoriasis	0.000149	0.000738	CcSEcCtD
Erythromycin—Anaphylactic shock—Betamethasone—psoriasis	0.000149	0.000737	CcSEcCtD
Erythromycin—Anaphylactic shock—Dexamethasone—psoriasis	0.000149	0.000737	CcSEcCtD
Erythromycin—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000148	0.00686	CbGpPWpGaD
Erythromycin—Feeling abnormal—Prednisolone—psoriasis	0.000147	0.000728	CcSEcCtD
Erythromycin—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000146	0.00677	CbGpPWpGaD
Erythromycin—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000145	0.00671	CbGpPWpGaD
Erythromycin—Hypersensitivity—Cyclosporine—psoriasis	0.000145	0.000715	CcSEcCtD
Erythromycin—Erythema multiforme—Methotrexate—psoriasis	0.000144	0.000714	CcSEcCtD
Erythromycin—Nausea—Mycophenolic acid—psoriasis	0.000144	0.000713	CcSEcCtD
Erythromycin—Feeling abnormal—Hydrocortisone—psoriasis	0.000144	0.000711	CcSEcCtD
Erythromycin—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000143	0.00661	CbGpPWpGaD
Erythromycin—Vertigo—Prednisone—psoriasis	0.000143	0.000707	CcSEcCtD
Erythromycin—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000143	0.000706	CcSEcCtD
Erythromycin—Tinnitus—Methotrexate—psoriasis	0.000142	0.000704	CcSEcCtD
Erythromycin—Anorexia—Dexamethasone—psoriasis	0.000142	0.000703	CcSEcCtD
Erythromycin—Anorexia—Betamethasone—psoriasis	0.000142	0.000703	CcSEcCtD
Erythromycin—Urticaria—Prednisolone—psoriasis	0.000142	0.000702	CcSEcCtD
Erythromycin—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000141	0.000698	CcSEcCtD
Erythromycin—Pain—Triamcinolone—psoriasis	0.000141	0.000695	CcSEcCtD
Erythromycin—Pruritus—Cyclosporine—psoriasis	0.000139	0.000687	CcSEcCtD
Erythromycin—Urticaria—Hydrocortisone—psoriasis	0.000139	0.000686	CcSEcCtD
Erythromycin—Abdominal pain—Hydrocortisone—psoriasis	0.000138	0.000682	CcSEcCtD
Erythromycin—Convulsion—Prednisone—psoriasis	0.000138	0.000682	CcSEcCtD
Erythromycin—Pruritus—Mycophenolate mofetil—psoriasis	0.000136	0.00067	CcSEcCtD
Erythromycin—Feeling abnormal—Triamcinolone—psoriasis	0.000135	0.00067	CcSEcCtD
Erythromycin—Diarrhoea—Cyclosporine—psoriasis	0.000134	0.000664	CcSEcCtD
Erythromycin—Discomfort—Prednisone—psoriasis	0.000134	0.000662	CcSEcCtD
Erythromycin—Erythema—Methotrexate—psoriasis	0.000133	0.000657	CcSEcCtD
Erythromycin—Hypersensitivity—Prednisolone—psoriasis	0.000132	0.000651	CcSEcCtD
Erythromycin—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000131	0.000648	CcSEcCtD
Erythromycin—Urticaria—Triamcinolone—psoriasis	0.000131	0.000645	CcSEcCtD
Erythromycin—Dysgeusia—Methotrexate—psoriasis	0.00013	0.000644	CcSEcCtD
Erythromycin—Dizziness—Cyclosporine—psoriasis	0.00013	0.000642	CcSEcCtD
Erythromycin—Anaphylactic shock—Prednisone—psoriasis	0.00013	0.000642	CcSEcCtD
Erythromycin—Decreased appetite—Betamethasone—psoriasis	0.00013	0.000641	CcSEcCtD
Erythromycin—Decreased appetite—Dexamethasone—psoriasis	0.00013	0.000641	CcSEcCtD
Erythromycin—Hypersensitivity—Hydrocortisone—psoriasis	0.000129	0.000636	CcSEcCtD
Erythromycin—Pain—Dexamethasone—psoriasis	0.000127	0.00063	CcSEcCtD
Erythromycin—Pain—Betamethasone—psoriasis	0.000127	0.00063	CcSEcCtD
Erythromycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000127	0.00587	CbGpPWpGaD
Erythromycin—Dizziness—Mycophenolate mofetil—psoriasis	0.000127	0.000626	CcSEcCtD
Erythromycin—SLC22A7—SLC-mediated transmembrane transport—CP—psoriasis	0.000126	0.00583	CbGpPWpGaD
Erythromycin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000125	0.00579	CbGpPWpGaD
Erythromycin—Vomiting—Cyclosporine—psoriasis	0.000125	0.000617	CcSEcCtD
Erythromycin—Rash—Cyclosporine—psoriasis	0.000124	0.000612	CcSEcCtD
Erythromycin—Anorexia—Prednisone—psoriasis	0.000124	0.000612	CcSEcCtD
Erythromycin—Pruritus—Hydrocortisone—psoriasis	0.000123	0.000611	CcSEcCtD
Erythromycin—Feeling abnormal—Betamethasone—psoriasis	0.000123	0.000608	CcSEcCtD
Erythromycin—Feeling abnormal—Dexamethasone—psoriasis	0.000123	0.000608	CcSEcCtD
Erythromycin—SLC22A7—Fluoropyrimidine Activity—TP53—psoriasis	0.000122	0.00565	CbGpPWpGaD
Erythromycin—Gastrointestinal pain—Dexamethasone—psoriasis	0.000122	0.000603	CcSEcCtD
Erythromycin—Gastrointestinal pain—Betamethasone—psoriasis	0.000122	0.000603	CcSEcCtD
Erythromycin—Vomiting—Mycophenolate mofetil—psoriasis	0.000122	0.000602	CcSEcCtD
Erythromycin—Hypersensitivity—Triamcinolone—psoriasis	0.000121	0.000599	CcSEcCtD
Erythromycin—Rash—Mycophenolate mofetil—psoriasis	0.000121	0.000597	CcSEcCtD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000121	0.00557	CbGpPWpGaD
Erythromycin—Vertigo—Methotrexate—psoriasis	0.000119	0.000591	CcSEcCtD
Erythromycin—Diarrhoea—Hydrocortisone—psoriasis	0.000119	0.00059	CcSEcCtD
Erythromycin—Urticaria—Dexamethasone—psoriasis	0.000118	0.000586	CcSEcCtD
Erythromycin—Urticaria—Betamethasone—psoriasis	0.000118	0.000586	CcSEcCtD
Erythromycin—Dizziness—Prednisolone—psoriasis	0.000118	0.000584	CcSEcCtD
Erythromycin—Abdominal pain—Betamethasone—psoriasis	0.000118	0.000583	CcSEcCtD
Erythromycin—Abdominal pain—Dexamethasone—psoriasis	0.000118	0.000583	CcSEcCtD
Erythromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000117	0.0054	CbGpPWpGaD
Erythromycin—Nausea—Cyclosporine—psoriasis	0.000117	0.000577	CcSEcCtD
Erythromycin—Pruritus—Triamcinolone—psoriasis	0.000116	0.000575	CcSEcCtD
Erythromycin—Dizziness—Hydrocortisone—psoriasis	0.000115	0.000571	CcSEcCtD
Erythromycin—Convulsion—Methotrexate—psoriasis	0.000115	0.00057	CcSEcCtD
Erythromycin—MLNR—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000115	0.0053	CbGpPWpGaD
Erythromycin—Nausea—Mycophenolate mofetil—psoriasis	0.000114	0.000563	CcSEcCtD
Erythromycin—Chest pain—Methotrexate—psoriasis	0.000113	0.00056	CcSEcCtD
Erythromycin—Decreased appetite—Prednisone—psoriasis	0.000113	0.000558	CcSEcCtD
Erythromycin—Rash—Prednisolone—psoriasis	0.000113	0.000557	CcSEcCtD
Erythromycin—Discomfort—Methotrexate—psoriasis	0.000112	0.000553	CcSEcCtD
Erythromycin—Vomiting—Hydrocortisone—psoriasis	0.000111	0.000549	CcSEcCtD
Erythromycin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00011	0.0051	CbGpPWpGaD
Erythromycin—Rash—Hydrocortisone—psoriasis	0.00011	0.000544	CcSEcCtD
Erythromycin—Confusional state—Methotrexate—psoriasis	0.000109	0.000541	CcSEcCtD
Erythromycin—Dizziness—Triamcinolone—psoriasis	0.000109	0.000537	CcSEcCtD
Erythromycin—Anaphylactic shock—Methotrexate—psoriasis	0.000109	0.000537	CcSEcCtD
Erythromycin—Feeling abnormal—Prednisone—psoriasis	0.000107	0.000529	CcSEcCtD
Erythromycin—Gastrointestinal pain—Prednisone—psoriasis	0.000106	0.000525	CcSEcCtD
Erythromycin—Nausea—Prednisolone—psoriasis	0.000106	0.000525	CcSEcCtD
Erythromycin—Pruritus—Betamethasone—psoriasis	0.000105	0.000522	CcSEcCtD
Erythromycin—Pruritus—Dexamethasone—psoriasis	0.000105	0.000522	CcSEcCtD
Erythromycin—Vomiting—Triamcinolone—psoriasis	0.000104	0.000517	CcSEcCtD
Erythromycin—Nausea—Hydrocortisone—psoriasis	0.000104	0.000513	CcSEcCtD
Erythromycin—Rash—Triamcinolone—psoriasis	0.000104	0.000512	CcSEcCtD
Erythromycin—Anorexia—Methotrexate—psoriasis	0.000103	0.000511	CcSEcCtD
Erythromycin—Urticaria—Prednisone—psoriasis	0.000103	0.00051	CcSEcCtD
Erythromycin—Abdominal pain—Prednisone—psoriasis	0.000103	0.000508	CcSEcCtD
Erythromycin—Diarrhoea—Dexamethasone—psoriasis	0.000102	0.000504	CcSEcCtD
Erythromycin—Diarrhoea—Betamethasone—psoriasis	0.000102	0.000504	CcSEcCtD
Erythromycin—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.94e-05	0.0046	CbGpPWpGaD
Erythromycin—Dizziness—Betamethasone—psoriasis	9.86e-05	0.000488	CcSEcCtD
Erythromycin—Dizziness—Dexamethasone—psoriasis	9.86e-05	0.000488	CcSEcCtD
Erythromycin—MLNR—Signaling Pathways—CCL20—psoriasis	9.8e-05	0.00453	CbGpPWpGaD
Erythromycin—Nausea—Triamcinolone—psoriasis	9.76e-05	0.000483	CcSEcCtD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.73e-05	0.0045	CbGpPWpGaD
Erythromycin—Hypersensitivity—Prednisone—psoriasis	9.57e-05	0.000473	CcSEcCtD
Erythromycin—Vomiting—Dexamethasone—psoriasis	9.48e-05	0.000469	CcSEcCtD
Erythromycin—Vomiting—Betamethasone—psoriasis	9.48e-05	0.000469	CcSEcCtD
Erythromycin—Decreased appetite—Methotrexate—psoriasis	9.43e-05	0.000466	CcSEcCtD
Erythromycin—SLCO1A2—SLC-mediated transmembrane transport—CP—psoriasis	9.4e-05	0.00435	CbGpPWpGaD
Erythromycin—Rash—Betamethasone—psoriasis	9.4e-05	0.000465	CcSEcCtD
Erythromycin—Rash—Dexamethasone—psoriasis	9.4e-05	0.000465	CcSEcCtD
Erythromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.32e-05	0.00431	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—HLA-C—psoriasis	9.3e-05	0.0043	CbGpPWpGaD
Erythromycin—Pain—Methotrexate—psoriasis	9.28e-05	0.000459	CcSEcCtD
Erythromycin—ABCB1—Allograft Rejection—IL13—psoriasis	9.24e-05	0.00428	CbGpPWpGaD
Erythromycin—Pruritus—Prednisone—psoriasis	9.19e-05	0.000454	CcSEcCtD
Erythromycin—Feeling abnormal—Methotrexate—psoriasis	8.94e-05	0.000442	CcSEcCtD
Erythromycin—Diarrhoea—Prednisone—psoriasis	8.88e-05	0.000439	CcSEcCtD
Erythromycin—Gastrointestinal pain—Methotrexate—psoriasis	8.87e-05	0.000439	CcSEcCtD
Erythromycin—Nausea—Betamethasone—psoriasis	8.86e-05	0.000438	CcSEcCtD
Erythromycin—Nausea—Dexamethasone—psoriasis	8.86e-05	0.000438	CcSEcCtD
Erythromycin—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.73e-05	0.00404	CbGpPWpGaD
Erythromycin—MLNR—GPCR ligand binding—CXCL8—psoriasis	8.73e-05	0.00404	CbGpPWpGaD
Erythromycin—MLNR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	8.7e-05	0.00402	CbGpPWpGaD
Erythromycin—Urticaria—Methotrexate—psoriasis	8.62e-05	0.000426	CcSEcCtD
Erythromycin—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.61e-05	0.00398	CbGpPWpGaD
Erythromycin—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.6e-05	0.00398	CbGpPWpGaD
Erythromycin—Dizziness—Prednisone—psoriasis	8.59e-05	0.000425	CcSEcCtD
Erythromycin—Abdominal pain—Methotrexate—psoriasis	8.58e-05	0.000424	CcSEcCtD
Erythromycin—ABCB1—Allograft Rejection—IL17A—psoriasis	8.51e-05	0.00394	CbGpPWpGaD
Erythromycin—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.47e-05	0.00392	CbGpPWpGaD
Erythromycin—Vomiting—Prednisone—psoriasis	8.25e-05	0.000408	CcSEcCtD
Erythromycin—Rash—Prednisone—psoriasis	8.19e-05	0.000405	CcSEcCtD
Erythromycin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.14e-05	0.00376	CbGpPWpGaD
Erythromycin—Hypersensitivity—Methotrexate—psoriasis	7.99e-05	0.000395	CcSEcCtD
Erythromycin—ABCB1—Allograft Rejection—IL12B—psoriasis	7.91e-05	0.00366	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—HLA-E—psoriasis	7.72e-05	0.00357	CbGpPWpGaD
Erythromycin—Nausea—Prednisone—psoriasis	7.71e-05	0.000381	CcSEcCtD
Erythromycin—Pruritus—Methotrexate—psoriasis	7.68e-05	0.00038	CcSEcCtD
Erythromycin—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.54e-05	0.00349	CbGpPWpGaD
Erythromycin—Diarrhoea—Methotrexate—psoriasis	7.42e-05	0.000367	CcSEcCtD
Erythromycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.19e-05	0.00333	CbGpPWpGaD
Erythromycin—Dizziness—Methotrexate—psoriasis	7.17e-05	0.000355	CcSEcCtD
Erythromycin—Vomiting—Methotrexate—psoriasis	6.9e-05	0.000341	CcSEcCtD
Erythromycin—Rash—Methotrexate—psoriasis	6.84e-05	0.000338	CcSEcCtD
Erythromycin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.74e-05	0.00312	CbGpPWpGaD
Erythromycin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.65e-05	0.00308	CbGpPWpGaD
Erythromycin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.49e-05	0.003	CbGpPWpGaD
Erythromycin—Nausea—Methotrexate—psoriasis	6.44e-05	0.000319	CcSEcCtD
Erythromycin—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	6.4e-05	0.00296	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.39e-05	0.00296	CbGpPWpGaD
Erythromycin—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	6.11e-05	0.00282	CbGpPWpGaD
Erythromycin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.82e-05	0.00269	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—IL10—psoriasis	5.78e-05	0.00268	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—IL4—psoriasis	5.63e-05	0.0026	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.5e-05	0.00254	CbGpPWpGaD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.49e-05	0.00254	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—SOCS1—psoriasis	5.4e-05	0.0025	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—TYK2—psoriasis	5.15e-05	0.00238	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—NDUFA5—psoriasis	5.14e-05	0.00238	CbGpPWpGaD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.12e-05	0.00237	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.1e-05	0.00236	CbGpPWpGaD
Erythromycin—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.04e-05	0.00233	CbGpPWpGaD
Erythromycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.01e-05	0.00232	CbGpPWpGaD
Erythromycin—MLNR—GPCR downstream signaling—CXCL8—psoriasis	4.93e-05	0.00228	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.79e-05	0.00222	CbGpPWpGaD
Erythromycin—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	4.78e-05	0.00221	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.66e-05	0.00215	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—NDUFA5—psoriasis	4.63e-05	0.00214	CbGpPWpGaD
Erythromycin—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.56e-05	0.00211	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—CXCL8—psoriasis	4.48e-05	0.00207	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—CYP2S1—psoriasis	4.37e-05	0.00202	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.31e-05	0.00199	CbGpPWpGaD
Erythromycin—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	4.3e-05	0.00199	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.18e-05	0.00194	CbGpPWpGaD
Erythromycin—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	4.1e-05	0.0019	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—NDUFA5—psoriasis	4.03e-05	0.00187	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—LEP—psoriasis	3.98e-05	0.00184	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—APOE—psoriasis	3.98e-05	0.00184	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—CYP2S1—psoriasis	3.93e-05	0.00182	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—NFKBIA—psoriasis	3.71e-05	0.00172	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.62e-05	0.00167	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.48e-05	0.00161	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—CYP2S1—psoriasis	3.43e-05	0.00159	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—IFNG—psoriasis	3.4e-05	0.00157	CbGpPWpGaD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.39e-05	0.00157	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.16e-05	0.00146	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.16e-05	0.00146	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—TYK2—psoriasis	3.04e-05	0.00141	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—NDUFA5—psoriasis	2.98e-05	0.00138	CbGpPWpGaD
Erythromycin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.97e-05	0.00137	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—NDUFA5—psoriasis	2.92e-05	0.00135	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.71e-05	0.00125	CbGpPWpGaD
Erythromycin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.71e-05	0.00125	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—CXCL8—psoriasis	2.65e-05	0.00122	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.6e-05	0.0012	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.57e-05	0.00119	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—CYP2S1—psoriasis	2.54e-05	0.00117	CbGpPWpGaD
Erythromycin—MLNR—Signaling by GPCR—IL6—psoriasis	2.52e-05	0.00116	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—CYP2S1—psoriasis	2.48e-05	0.00115	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—JUN—psoriasis	2.46e-05	0.00114	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—NFKB1—psoriasis	2.37e-05	0.0011	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.29e-05	0.00106	CbGpPWpGaD
Erythromycin—ABCB1—Allograft Rejection—TNF—psoriasis	2.2e-05	0.00102	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—NDUFA5—psoriasis	2.2e-05	0.00102	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.19e-05	0.00101	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—VEGFA—psoriasis	2.15e-05	0.000994	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—CARM1—psoriasis	2.13e-05	0.000987	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—STAT3—psoriasis	2.13e-05	0.000984	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.06e-05	0.000953	CbGpPWpGaD
Erythromycin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.04e-05	0.000946	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2e-05	0.000923	CbGpPWpGaD
Erythromycin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.95e-05	0.000902	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—CARM1—psoriasis	1.92e-05	0.000888	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—CYP2S1—psoriasis	1.87e-05	0.000865	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.8e-05	0.00083	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—NDUFA5—psoriasis	1.76e-05	0.000813	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—CARM1—psoriasis	1.68e-05	0.000775	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.64e-05	0.000758	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—TP53—psoriasis	1.62e-05	0.000751	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—CYP2S1—psoriasis	1.49e-05	0.000691	CbGpPWpGaD
Erythromycin—MLNR—Signaling Pathways—IL6—psoriasis	1.49e-05	0.000688	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.45e-05	0.000671	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.4e-05	0.000646	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—NDUFA5—psoriasis	1.36e-05	0.000627	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—CAT—psoriasis	1.31e-05	0.000607	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.27e-05	0.000586	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—CARM1—psoriasis	1.24e-05	0.000573	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—CARM1—psoriasis	1.21e-05	0.00056	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—CAT—psoriasis	1.18e-05	0.000546	CbGpPWpGaD
Erythromycin—ABCC1—Disease—HLA-A—psoriasis	1.17e-05	0.000543	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—CYP2S1—psoriasis	1.15e-05	0.000533	CbGpPWpGaD
Erythromycin—ABCC1—Disease—APOE—psoriasis	1.1e-05	0.000507	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.09e-05	0.000502	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—CAT—psoriasis	1.03e-05	0.000477	CbGpPWpGaD
Erythromycin—ABCC1—Disease—NOS2—psoriasis	1.02e-05	0.000472	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—APOE—psoriasis	1.02e-05	0.000472	CbGpPWpGaD
Erythromycin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	9.58e-06	0.000443	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—APOE—psoriasis	9.18e-06	0.000425	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—CARM1—psoriasis	9.14e-06	0.000423	CbGpPWpGaD
Erythromycin—SLCO1A2—Metabolism—PPARG—psoriasis	8.88e-06	0.000411	CbGpPWpGaD
Erythromycin—ABCC1—Disease—TYK2—psoriasis	8.37e-06	0.000387	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—APOE—psoriasis	8.01e-06	0.00037	CbGpPWpGaD
Erythromycin—ABCC1—Metabolism—PPARG—psoriasis	8e-06	0.00037	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.83e-06	0.000362	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—CAT—psoriasis	7.62e-06	0.000352	CbGpPWpGaD
Erythromycin—ABCC1—Disease—CD4—psoriasis	7.57e-06	0.00035	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—CAT—psoriasis	7.45e-06	0.000345	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—CARM1—psoriasis	7.29e-06	0.000337	CbGpPWpGaD
Erythromycin—CYP3A7—Metabolism—PPARG—psoriasis	6.97e-06	0.000323	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.82e-06	0.000315	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—APOE—psoriasis	5.92e-06	0.000274	CbGpPWpGaD
Erythromycin—ABCC1—Disease—STAT3—psoriasis	5.86e-06	0.000271	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—APOE—psoriasis	5.79e-06	0.000268	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—CARM1—psoriasis	5.63e-06	0.00026	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—CAT—psoriasis	5.62e-06	0.00026	CbGpPWpGaD
Erythromycin—CYP2B6—Metabolism—PPARG—psoriasis	5.16e-06	0.000239	CbGpPWpGaD
Erythromycin—CYP3A5—Metabolism—PPARG—psoriasis	5.04e-06	0.000233	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—CAT—psoriasis	4.49e-06	0.000208	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—APOE—psoriasis	4.37e-06	0.000202	CbGpPWpGaD
Erythromycin—ABCC1—Disease—IL6—psoriasis	4.09e-06	0.000189	CbGpPWpGaD
Erythromycin—ABCB1—Metabolism—PPARG—psoriasis	3.8e-06	0.000176	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—APOE—psoriasis	3.49e-06	0.000161	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—CAT—psoriasis	3.46e-06	0.00016	CbGpPWpGaD
Erythromycin—CYP1A2—Metabolism—PPARG—psoriasis	3.04e-06	0.00014	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—APOE—psoriasis	2.69e-06	0.000124	CbGpPWpGaD
Erythromycin—CYP3A4—Metabolism—PPARG—psoriasis	2.34e-06	0.000108	CbGpPWpGaD
